DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election without traverse of Group I (claims 1-9) in the reply filed on 9/29/26 is acknowledged.
Claims 10-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 9/29/26 with a condition to rejoin if the elected subject matter is allowed.
Claim Rejections - 35 USC § 112.
Claims1-2 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-2 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection
Here, applicant has not described a reasonable number of members of the genus now claimed that might identify some agents that fall within the scope of the claim.
The instant claims are often referred to as “reach-through” claims, where an applicant attempts to obtain patent protection on an invention not yet discovered. The Court of Appeals for the Federal Circuit addressed claims of this sort in great detail at the University of Rochester v. G.D. Searle and Co. (69 USPQ 2nd 1886, CAFC 2004). In Rochester, the Federal Circuit upheld the district court's ruling that patent claims which recited administration of compounds not disclosed, but rather to be identified in a screening assay, were invalid on their face. While the instant claims are drawn to compositions composition, comprising: a polymeric mixture comprising a hydrophobic component and a hydrophilic component, wherein the hydrophobic component has a lower water solubility than the hydrophilic component; and one or more molecules for disrupting bacterial communication, the situation is analogous to that in Rochester. Since the specification does not disclose to the public the structures claimed, it does not meet the written description requirement of 35 USC § 112, first paragraph.
To avoid this rejection the Examiner, suggest that claim 3 be included as part of claim 1.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 1-5 and 9 is/are rejected under 35 U.S.C. 102(a2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Bose et al. (Materials Today Chemistry 8(2018 110-120).
Bose teaches a composition comprising PCL-PEG coated with curcumin (see abstract) as required by instant claims 1-4), wherein the curcumin is the main active component derived from the rhizomes of turmeric plant (CurcumalongaL.) i.e., a molecule for disrupting bacteria(as required) and therefore a molecule for disrupting bacterial communication (as required by instant claims1and 7) with a ratio of 1:1 (see para.2.1.2 drug polymer coating as required by instant claim 4). With regards to instant claim 5, the compounds PCL-PEG are anticipated or intrinsically to be of the claimed molecular weight of 5, 000 to 100,000; and wherein the hydrophilic component comprises polyethylene glycol having a molecular weight ranging from 200 to 1,000,000. Additionally, Bose teaches that the polymer solution and the curcumin underwent mixing (see para 2.3.2, as required by instant claim 9).
However, Bose fails to teach, wherein the one or more molecules for disrupting bacterial communication comprises an anti-quorum sensing molecule, a derivative, or analogue thereof; or a quorum quenching molecule, a derivative, or analogue thereof
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1-5 is/are rejected under 35 U.S.C. 103 as being unpatentable over Bose et al. (Materials Today Chemistry 8(2018 110-120) in view of Lowe et al. (Polym. Chem. (2015) 5(2) 198-212) and further in view of Bouyahya et al. Molecules (2022) 27(5)1484
Bose teaches a composition comprising PCL-PEG coated with curcumin (see abstract) as required by instant claims 1-4), wherein the curcumin is the main active component derived from the rhizomes of turmeric plant (CurcumalongaL.) i.e., a molecule for disrupting bacteria(as required) and therefore a molecule for disrupting bacterial communication (as required by instant claims1and 7) with a ratio of 1:1 (see para.2.1.2 drug polymer coating as required by instant claim 4). With regards to instant claim 5, the compounds PCL-PEG are anticipated or intrinsically to be of the claimed molecular weight of 5, 000 to 100,000; and wherein the hydrophilic component comprises polyethylene glycol having a molecular weight ranging from 200 to 1,000,000. Additionally, Bose teaches that the polymer solution and the curcumin underwent mixing (see para 2.3.2, as required by instant claim 9).
However, Bose fails to teach, wherein the one or more molecules for disrupting bacterial communication comprises an anti-quorum sensing molecule, a derivative, or analogue thereof; or a quorum quenching molecule, a derivative, or analogue thereof
Lowe teaches that microbial absorption on biomedical systems and PEG polymer is the most widely used antifouling agent (see abstract).
Bouyaha teaches quorum (i.e., QS0 is an inter cellular communication system between the same strain or different strains that co-ordinates the transcriptional regulation of genes responsible for several vital functions of these microorganisms (see abstract and Introduction).
Therefore, one of ordinary skills in the art One would have been motivated to combine these references and make the modification because they are drawn to same technical fields (constituted with same ingredients and share common utilities, and pertinent to the problem which applicant concerns about. MPEP 2141.01(a)
Additionally, the person of ordinary skill in the art, having the laboratory walls hung would have been motivated to combine the teachings of the cited prior art and form a composition comprising by expanding the teachings of Bose above , incorporating Lowe’s and Bouyaha’ s teaching to result in the instant claimed invention with a reasonable expectation of success The person of ordinary skill in the art would have been motivated to do so to attain the known advantages of the advantages treatments as taught by the references, and further would have been motivated to monitor the results of the treatment using multiple parameters, to get a better overall indication of efficacy. Accordingly, the invention as claimed is prima facie obvious.
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHIRLEY V GEMBEH whose telephone number is (571)272-8504. The examiner can normally be reached M-F 9am-6pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A. Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SHIRLEY V GEMBEH/Primary Examiner, Art Unit 1615 10/22/26